JWJan Wesche

Jan Wesche

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Wesche has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detection of Anti-Platelet Factor 4 Antibodies in Acute and Chronic Thromboembolic Disease—A Pilot Study

    by Annabell Trunk, Jan Wesche, Stella Jacobi, Marina Bruch-Oms, Donata Metzler, Eva Herrmann, Thomas Thiele, Edelgard Lindhoff-Last

    Heterogeneous antibodies directed against platelet factor 4 (PF4-Abs) are associated with heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Emerging evidence suggests that these antibodies may also occur in other thromboembolic diseases. In this pilot study, we assessed the prevalence of PF4-Abs in patients with acute thromboembolism and in patients with thromboembolic antiphospholipid syndrome (APS), a chronic autoimmune thrombophilia. Forty patients with acute thromboembolism and 43 patients with APS were included. Both heparin-dependent and heparin-independent PF4-Abs were evaluated using multiple assay platforms, including a prototype chemiluminescence assay for heparin-independent PF4-Abs, an anti-PF4/polyanion IgG chemiluminescence assay, a latex agglutination assay detecting anti-PF4/polyanion IgG/IgM/IgA antibodies, an anti-PF4/heparin IgG ELISA, and functional platelet activation tests. Across the different assays, positivity in at least one assay was observed in 27.5% (11/40) of patients with acute thromboembolism and 27.9% (12/43) of patients with APS. In most antibody-positive patients, no recent heparin exposure was documented. Functional platelet activation was predominantly absent, arguing against a classical HIT- or VITT-like mechanism. Overall, these results demonstrate assay-dependent PF4-Ab positivity in a substantial proportion of patients with acute and chronic thromboembolic conditions. Their clinical and pathogenic relevance remains unclear and warrants further investigation.

  • Reducing Bacterial Contamination of Blood Bags with a Double Knot

    by Kathleen Selleng, Halima Ismail, Christian Kohler, Jan Wesche, Jessica Fuhrmann, Anne Kohler, Claudia Wiede, Vivien Huj, Yazid Ibrahim, Evgeny A. Idelevich, et al.

  • Open Access

    Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)-like Syndrome: A Case Report and Some Considerations on a Novel Diagnostic and Therapeutic Challenge

    by Lorenzo Delfino, Sara Moruzzi, Michela Carrillo, Silvia Suardi, Sabrina Genesini, Linda Schönborn, Jan Wesche, Giulia Salandini, Carlotta Spillere, Gabriele Costa, et al.

    Background and Clinical Significance: Disorders caused by platelet-activating antibodies targeting platelet factor 4 (PF4) are recognized as the cause of severe thrombotic events and are not restricted to heparin-induced thrombocytopenia (HIT). Case Presentation: We report a 67-year-old man with thrombocytopenia and extensive portal-splenic-mesenteric vein thrombosis complicated by intestinal ischemia. Despite intravenous unfractionated heparin (UFH), his condition worsened toward pulmonary embolism, septic shock, and multi-organ failure. Thrombolysis with alteplase was also ineffective. Both thrombophilia testing and autoimmune panels were negative, including those for antiphospholipid syndrome. An anti-PF4 immune thrombotic disorder was hypothesized. Therefore, argatroban was initiated instead of UFH therapy and intravenous immune globulin (IVIG) was administered. The platelet count increased and the patient’s clinical condition progressively improved. An anti-PF4/heparin assay on a blood sample collected before IVIG was highly positive. Platelet activation assays did not demonstrate an increased activation after the addition of heparin (the Heparin-Induced Platelet Activation [HIPA] assay was negative) though increased activation was observed with the addition of PF4 (the PF4-Induced Platelet Activation [PIPA] assay was positive), thus defining a VITT-like syndrome. Conclusions: This case report highlights the crucial function of having adequate laboratory facilities available to disentangle different anti-PF4 disorders for an accurate definition of a specific diagnosis, such as VITT-like syndrome, thereby allowing for the most appropriate therapeutic management of these complex pathological conditions. The clinical suspicion of an anti-PF4 immune disorder should be considered in cases of severe, otherwise unexplained, thrombotic events associated with thrombocytopenia. Specific tests like HIPA and PIPA are essential for definitive diagnosis.

  • Open Access

    Immobilized Enzymes for ABO‐Independent Blood Cell Transfusions

    by Christina Möller, Fabian Pohlschröder, Jan Wesche, Paula Schmiade, Merle Baselau, Kristian Wende, Berenika Stloukalová, Dominique Böttcher, Andreas Greinacher, Uwe T. Bornscheuer, et al.

    The transfusion of blood products requires ABO compatibility due to A and B antigens on blood cells and their corresponding antibodies in plasma. The supply of red cell concentrates (RCCs) and platelet concentrates (PCs) is challenged by rising demand and declining numbers of donors. To counteract the supply limitations, a method is developed to generate universal RCCs and PCs. For this, the A antigen is enzymatically removed by two enzymes from Flavonifractor plautii working in concert and the B antigen is removed by galactosidases from Pedobacter panaciterrae (PpaGal_WT or the variant PpaGal_W260Y) and Akkermansia muciniphila (AmGH110A or AmGH110B). The glycosidases are immobilized on polymethacrylate microparticles and are removed by the 200 µm filter of the mandatory transfusion set before the transfusion to avoid a possible immune reaction by the enzymes. B‐positive red cells in RCCs are reduced below a 4% background signal within 48 h at 2–6 °C. Pooled PCs showed a 34 ± 14% reduction in B‐positive cells and a residual A‐positive platelet population of 4 ± 1% after 4 h of treatment at 20–24 °C. This approach efficiently generates ABO‐universal RCCs and PCs while preserving blood quality and reducing incompatibility risks.


  • Open Access

    Platelet-activating histone/antihistone IgG complexes in anti-PF4–negative thrombosis and thrombocytopenia syndrome

    by Max Esefeld, Stefan Handtke, Rainer Kaiser, Leo Nicolai, Lea Di Fina, Dario Rossaro, Jan Wesche, Justina Rath, Ann-Christin Wienrich, Till Hoffmann, et al.

    Thrombosis and thrombocytopenia syndromes (TTS) describe immune-mediated thrombotic adverse reactions after vaccination against COVID-19. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a well-known subentity of TTS, caused by adenovirus vector–based vaccines. VITT is mediated by anti-platelet factor 4 (PF4) immunoglobulin G (IgG) antibodies, activating platelets via Fc-γ IIa receptors (FcγRIIa). We describe clinical and serological features of 18 patients with anti-PF4/heparin enzyme-linked immunosorbent assay (ELISA)–negative TTS in temporal relationship to messenger RNA (mRNA)–based COVID-19 vaccination. Symptoms began at a median of 7 (range 1 - 61) days after vaccination. Patients showed thrombocytopenia (platelet count 59 × 103/μL; range, 0 to 127 × 103/μL); petechiae (n = 7), venous thromboembolism (n = 11), arterial thrombosis (n = 6), disseminated intravascular coagulation (n = 1), and combined arterial and venous thromboses (n = 1). Twelve sera-induced FcγRIIa-dependent and caspase-independent procoagulant activation of platelets indicated by phosphatidylserine exposure and CD62P expression. We found histones precipitated with IgG fractions of TTS sera. Antibodies binding to histones were found in 8 of 12 platelet-activating sera. Ex vivo–generated histone/antihistone IgG complexes strongly activated platelets via FcγRIIa, whereas antihistone IgG alone did not. Platelet autoantibodies were detected in 7 of 12 sera targeting glycoprotein (GP) IIb/IIIa (n = 5), GPIb/IX (n = 5), and GPIa/IIa (n = 3). However, sera containing platelet anti-GPIIb/IIIa autoantibodies activated also platelets from a patient with Glanzmann thrombasthenia, making it unlikely that these autoantibodies are causative for platelet activation. Finally, 2 of 114 healthy vaccinees developed antihistone antibodies after mRNA-based COVID-19 vaccination. Our data indicate a new subentity of TTS associated with platelet-activating histone/antihistone IgG complexes. Further studies are warranted to characterize the biological and clinical role of post-mRNA–based vaccination antihistone antibodies. The SeCo trial was registered at www.ClinicalTrials.gov as #NCT04370119.


  • Open Access

    Identification and Protein Engineering of Galactosidases for the Conversion of Blood Type B to Blood Type O

    by Christina Möller, Henrik Terholsen, Ole Schmöker, Thi Linh Anne Lê, Jan Wesche, Paula Schmiade, Esther Eppendorfer, Niklas Rimkus, Britta Girbardt, Dominique Böttcher, et al.

    The supply of blood products such as red blood cells poses a challenge due to rising demand and declining donor numbers. Careful matching of blood products of different types is required. Only type O of the blood types A, B, AB and O can be received by any patient without transfusion incompatibilities. Therefore, O‐type blood can be considered “universal blood” and is especially needed in emergency situations. In this study, we focused on the conversion of the B antigen by enzymatic deglycosylation to generate the H antigen determining O‐type blood. For this, we characterized several previously unstudied α‐1,3‐galactosidases belonging to the GH110 family. Our findings revealed that the α‐1,3‐galactosidase from Pedobacter panaciterrae (PpaGal) exhibits superior efficiency compared to previously described galactosidases. We further increased the activity of PpaGal by 2.5‐fold using site‐directed mutagenesis. Moreover, we solved two crystal structures of PpaGal, one in the apo‐state and another in complex with d ‐galactose. The combination of our mutagenesis study with the solved crystal structures provides valuable information to guide further optimization of PpaGal or other B antigen converting enzymes paving the way for the easier production of universal blood from B‐type blood.


  • Maternal Anti-PF4 Antibodies as Cause of Neonatal Stroke

    by Silke Häusler, Linda Schönborn, Johann Gradl, Janne Cadamuro, Katja Steinbrücker, Marta Broto, Marta Palicio, Kathrin Budde, Jan Wesche, Andreas Greinacher, et al.


  • Open Access

    Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms

    by Carlo Zaninetti, Leonard Vater, Lars Kaderali, Carl C. Crodel, Tina M. Schnöder, Jessica Fuhrmann, Leonard Swensson, Jan Wesche, Carmen Freyer, Andreas Greinacher, et al.


  • Top Cited Papers
    Open Access

    Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

    by Linda Schönborn, Olga Esteban, Jan Wesche, Paulina Dobosz, Marta Broto, Sara Rovira Puig, Jessica Fuhrmann, Raquel Torres, Josep Serra, Roser Llevadot, et al.

    Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4 antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT), respectively. Diagnostic and treatment considerations differ somewhat between HIT and VITT. We identified patients with thrombocytopenia and thrombosis without proximate heparin exposure or adenovirus-based vaccination who tested strongly positive by PF4/polyanion enzyme-immunoassays and negative/weakly positive by heparin-induced platelet activation (HIPA) test but strongly positive by PF4-induced platelet activation (PIPA) test (ie, VITT-like profile). We tested these patients by a standard chemiluminescence assay that detects anti-PF4/heparin antibodies found in HIT (HemosIL AcuStar HIT-IgG(PF4-H)) as well as a novel chemiluminescence assay for anti-PF4 antibodies found in VITT. Representative control sera included an exploratory anti-PF4 antibody-positive but HIPA-negative/weak cohort obtained before 2020 (n = 188). We identified 9 patients with a clinical-pathological profile of a VITT-like disorder in the absence of proximate heparin or vaccination, with a high frequency of stroke (arterial, n = 3; cerebral venous sinus thrombosis, n = 4), thrombocytopenia (median platelet count nadir, 49 × 109/L), and hypercoagulability (greatly elevated D-dimer levels). VITT-like serological features included strong reactivity by PIPA (aggregation <10 minutes in 9/9 sera) and positive testing in the novel anti-PF4 chemiluminescence assay (3/9 also tested positive in the anti-PF4/heparin chemiluminescence assay). Our exploratory cohort identified 13 additional patient sera obtained before 2020 with VITT-like anti-PF4 antibodies. Platelet-activating VITT-like anti-PF4 antibodies should be considered in patients with thrombocytopenia, thrombosis, and very high D-dimer levels, even without a proximate exposure to heparin or adenovirus vector vaccines.


  • Open Access

    FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation

    by Vanessa Riechert, Sascha Hein, Mayken Visser, Mathias Zimmermann, Jan Wesche, Philipp A. Adams, Samuel A. Theuerkauf, Arezoo Jamali, Andrea Wangorsch, Andreas Reuter, et al.